NYSEAMERICAN:PTN Palatin Technologies (PTN) Stock Price, News & Analysis $1.70 -0.11 (-6.08%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.66▼$1.8150-Day Range N/A52-Week Range$1.43▼$5.65Volume67,029 shsAverage Volume84,250 shsMarket Capitalization$27.44 millionP/E RatioN/ADividend YieldN/APrice Target$17.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort Interest Get Palatin Technologies alerts: Email Address Palatin Technologies MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside900.0% Upside$17.00 Price TargetShort InterestHealthy7.67% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.41) to ($0.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.38 out of 5 stars 3.5 Analyst's Opinion Consensus RatingPalatin Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePalatin Technologies has only been the subject of 1 research reports in the past 90 days.Read more about Palatin Technologies' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.67% of the float of Palatin Technologies has been sold short.Short Interest Ratio / Days to CoverPalatin Technologies has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Palatin Technologies has recently decreased by 11.28%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPalatin Technologies does not currently pay a dividend.Dividend GrowthPalatin Technologies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PTN. Previous Next 1.1 News and Social Media Coverage Search Interest8 people have searched for PTN on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.MarketBeat Follows6 people have added Palatin Technologies to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Palatin Technologies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.10% of the stock of Palatin Technologies is held by insiders.Percentage Held by InstitutionsOnly 11.50% of the stock of Palatin Technologies is held by institutions.Read more about Palatin Technologies' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Palatin Technologies are expected to grow in the coming year, from ($2.41) to ($0.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Palatin Technologies is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Palatin Technologies is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPalatin Technologies has a P/B Ratio of 170.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Palatin Technologies Stock (NYSEAMERICAN:PTN)Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.Read More PTN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PTN Stock News HeadlinesJuly 19, 2024 | finance.yahoo.comPalatin Technologies Inc (PTN.BE)June 21, 2024 | prnewswire.comPalatin Announces Exercise of Warrants for Approximately $6.1 Million Gross ProceedsJuly 27, 2024 | True Market Insiders (Ad)The #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…June 20, 2024 | prnewswire.comPalatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)June 12, 2024 | prnewswire.comPalatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of ObesityMay 20, 2024 | markets.businessinsider.comPalatin Technologies Upgraded to Buy: What Does It Mean for the Stock?May 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Palatin Technologies (PTN) and Prestige Consumer Healthcare (PBH)May 16, 2024 | msn.comPalatin Technologies, Inc. (AMEX:PTN) Q3 2024 Earnings Call TranscriptJuly 27, 2024 | True Market Insiders (Ad)The #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…May 16, 2024 | finance.yahoo.comQ3 2024 Palatin Technologies Inc Earnings CallMay 16, 2024 | finance.yahoo.comPalatin Technologies Inc (PTN) (Q3 2024) Earnings Call Transcript Highlights: Navigating ...May 15, 2024 | markets.businessinsider.comPalatin Technologies Inc. Q3 Loss DecreasesMay 15, 2024 | prnewswire.comPalatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdateMay 9, 2024 | prnewswire.comPalatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024May 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Palatin Technologies (PTN)May 3, 2024 | markets.businessinsider.comBuy Rating Endorsed for Palatin Technologies Amidst Promising Obesity Treatment AdvancementsMay 2, 2024 | msn.comPalatin spikes as FDA clears mid-stage trial for weight loss therapyMay 2, 2024 | seekingalpha.comPalatin gets FDA OK to test weight loss therapy with Eli Lilly’s tirzepatideSee More Headlines Receive PTN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Palatin Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:PTN Previous SymbolNYSE:PTN CUSIPN/A CIK911216 Webwww.palatin.com Phone(609) 495-2200Fax609-495-2202Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$17.00 High Stock Price Target$17.00 Low Stock Price Target$17.00 Potential Upside/Downside+900.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,540,000.00 Net Margins-445.12% Pretax Margin-601.37% Return on EquityN/A Return on Assets-242.91% Debt Debt-to-Equity RatioN/A Current Ratio1.20 Quick Ratio1.20 Sales & Book Value Annual Sales$4.85 million Price / Sales5.66 Cash FlowN/A Price / Cash FlowN/A Book Value$0.01 per share Price / Book170.00Miscellaneous Outstanding Shares16,140,000Free Float14,991,000Market Cap$27.44 million OptionableNot Optionable Beta1.00 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Carl Spana Ph.D. (Age 62)Co-Founder, President, CEO & Director Comp: $979kMr. Stephen T. Wills CPA (Age 67)MST, CFO, COO, Executive VP, Treasurer & Secretary Comp: $910.55kBurns McClellanVice President of Investor RelationsMr. Stephen A. Slusher Esq.Chief Legal OfficerDr. Michael B. Raizman M.D.Chief Medical OfficerMr. James E. Hattersley (Age 64)Senior Vice President of Business Development Mr. John Dodd Ph.D.Senior Vice President of Preclinical DevelopmentMr. Robert JordanSenior Vice President of Program OperationsMore ExecutivesKey CompetitorsSenti BiosciencesNASDAQ:SNTITribute Pharmaceuticals CanadaOTCMKTS:TBUFFOramed PharmaceuticalsNASDAQ:ORMPCardiff OncologyNASDAQ:CRDFSagimet BiosciencesNASDAQ:SGMTView All CompetitorsInsidersRobert K Deveer JrBought 6,000 shares on 4/11/2024Total: $12,720.00 ($2.12/share)Robert K Deveer JrSold 11,700 sharesTotal: $23,400.00 ($2.00/share)Stephen T WillsSold 4,998 sharesTotal: $12,544.98 ($2.51/share)Alan W DuntonSold 200 sharesTotal: $496.00 ($2.48/share)View All Insider Transactions PTN Stock Analysis - Frequently Asked Questions How have PTN shares performed this year? Palatin Technologies' stock was trading at $4.00 at the start of the year. Since then, PTN shares have decreased by 57.5% and is now trading at $1.70. View the best growth stocks for 2024 here. How were Palatin Technologies' earnings last quarter? Palatin Technologies, Inc. (NYSEAMERICAN:PTN) issued its earnings results on Wednesday, May, 15th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.03. When did Palatin Technologies' stock split? Palatin Technologies shares reverse split before market open on Wednesday, August 31st 2022. The 1-25 reverse split was announced on Wednesday, August 31st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 31st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Palatin Technologies? Shares of PTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Palatin Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Palatin Technologies investors own include Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Trevena (TRVN), Alliqua Biomedical (ALQA), Catalyst Pharmaceuticals (CPRX) and AVEO Pharmaceuticals (AVEO). This page (NYSEAMERICAN:PTN) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palatin Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palatin Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
